Bruker Co. (NASDAQ:BRKR) has received an average rating of “Hold” from the sixteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $28.90.

A number of equities research analysts have recently weighed in on the company. BidaskClub downgraded Bruker from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Goldman Sachs Group reiterated a “sell” rating and issued a $24.00 price target on shares of Bruker in a report on Tuesday, September 26th. J P Morgan Chase & Co upgraded Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 price target for the company in a report on Friday, November 3rd. Citigroup boosted their price target on Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Finally, Cowen restated a “hold” rating and set a $29.00 price objective on shares of Bruker in a research note on Friday, November 3rd.

In other Bruker news, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the transaction, the vice president now owns 60,524 shares in the company, valued at approximately $1,813,904.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 35.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Koch Industries Inc. boosted its position in Bruker by 2,573.5% during the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock worth $324,000 after acquiring an additional 322,252 shares during the period. AJO LP acquired a new position in Bruker during the 2nd quarter worth $46,075,000. Cubist Systematic Strategies LLC boosted its position in Bruker by 186.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock worth $475,000 after acquiring an additional 10,723 shares during the period. Victory Capital Management Inc. boosted its position in Bruker by 6.8% during the 2nd quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock worth $55,667,000 after acquiring an additional 123,322 shares during the period. Finally, Verition Fund Management LLC boosted its position in Bruker by 95.6% during the 2nd quarter. Verition Fund Management LLC now owns 26,891 shares of the medical research company’s stock worth $776,000 after acquiring an additional 13,140 shares during the period. Institutional investors own 65.58% of the company’s stock.

Bruker (BRKR) traded up $0.05 during mid-day trading on Thursday, reaching $35.18. The company’s stock had a trading volume of 729,903 shares, compared to its average volume of 631,908. Bruker has a 52 week low of $21.03 and a 52 week high of $36.53. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65. The stock has a market cap of $5,470.00, a P/E ratio of 31.07, a PEG ratio of 3.07 and a beta of 1.05.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The business had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. During the same period in the previous year, the business earned $0.32 EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. equities research analysts anticipate that Bruker will post 1.19 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 22nd. Shareholders of record on Monday, December 4th will be given a dividend of $0.04 per share. The ex-dividend date of this dividend is Friday, December 1st. This represents a $0.16 dividend on an annualized basis and a yield of 0.45%. Bruker’s dividend payout ratio (DPR) is presently 17.02%.

COPYRIGHT VIOLATION WARNING: “Bruker Co. (BRKR) Receives Average Rating of “Hold” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/30/bruker-co-brkr-receives-average-rating-of-hold-from-analysts.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with MarketBeat.com's FREE daily email newsletter.